CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Made In Germany For the World Is Hopp’s Vision

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Curevac_White_House
Daniel Menichella (far right) was among biopharma execs meeting President Trump in March • Source: Official White House Photo by Andrea Hanks

The German majority owner of CureVac AG has declared his commitment to making the company’s potential coronavirus vaccine available to people globally, from Germany. His comments come after Donald Trump was rumored to have offered the company a large amount of money to make it exclusively available to the US. Meanwhile, CureVac’s CEO, who met the US president earlier this month along with other biopharma executives, has been replaced.

Dietmar Hopp, the German software billionaire and biotech investor who owns more than 80% of Tübingen-based CureVac’s shares, said he...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip